Semaglutide 5mg

Name: Semaglutide 5mg
SKU: PL-5MG-PL02
Price: 185.00 USD
Availability: InStock

Brands PeptideLion

$185.00

out of stock

Sku:

PL-5MG-PL02

Brands: PeptideLion

Description

Overview

What is Semaglutide?

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists, or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). For that reason, health care providers have used semaglutide for more than 15 years to treat Type 2 diabetes.

But GLP-1 in higher amounts also interacts with the parts of the brain that suppress your appetite and signal you to feel full. When used in conjunction with diet and exercise, it can cause significant weight loss — and a reduced risk of cancer, diabetes, and heart disease — in people who are obese or overweight.

Who Is a Good Candidate for Semaglutide?

“A good candidate for Ozempic is someone who is comfortable providing a weekly self-injection, has a medical history of type 2 diabetes and an elevated body mass index (BMI) of at least 27,” says Dr. Saunders. Similarly, a good candidate for Rybelsus has a medical history of type 2 diabetes and a BMI of 27 or more, she says.

A good candidate for Wegovy must also be comfortable with a weekly self-injection and have a BMI of 30 (with or without weight-related health complications) or a BMI of at least 27 with at least one weight-related health complication (like high cholesterol or hypertension), explains Dr. Saunders.

Scientific Information

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous as well as oral dosage forms (the first approved oral GLP-1 receptor agonist). It has been approved as a second-line treatment option for better glycaemic control in type 2 diabetes and is currently under scrutiny for anti-obesity purposes. Semaglutide has been proven to be safe in adults and elderly patients with renal or hepatic disorders, demanding no dose modification. Cardiovascular (CV) outcome trials established that it can reduce various CV risk factors in patients with established CV disorders. Semaglutide is well tolerated with no risk of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse effects. A large population affected with COVID-19 infection were diabetic; therefore, the use of semaglutide in diabetes as well as CV patients would be very supportive in maintaining the health care system during this pandemic situation. Hence, this peptidic drug can be truly considered a quintessential GLP-1 agonist for the management of type 2 diabetes.

Research Highlights

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the activity of GLP-1, a hormone released in the intestine after eating. GLP-1 triggers insulin production, thereby reducing blood sugar levels, and interacts with parts of the brain to decrease hunger and promote feelings of satiety. Different forms of semaglutide are FDA-approved for treating type 2 diabetes or obesity (in conjunction with diet and exercise).

If you are obese, overweight, or struggling to lose weight, a simple peptide named semaglutide may be a game-changer. While the name is not simple, this GLP-1 RA mimics the GLP-1 hormone, which is released in the digestive system. As a result, it suppresses appetite, which is why when combined with a better diet and exercise, this peptide can lead to weight loss. It is also the first drug in seven years to be approved by the FDA to treat obesity, which is an impressive feat in itself. Semaglutide is more effective than other GLP-1 RAs in terms of improvement in glycemia and other cardio-metabolic risk factors among individuals with T2DM.